1. Optimal Testosterone Control and Eligard®
Bertrand Tombal, Richard Berges 
European Urology Supplements 
Volume 6, Issue 12, Pages (July 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Eligard 1, 3, and 6 suppress testosterone levels below the castration level of 20ng/dl [33]. Reprinted from Sartor O, Eligard® 6: a new form of treatment for prostate cancer, Eur Urol Suppl 2006;5:905–10 with permission from the European Association of Urology.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Eligard 1, 3, and 6 show an increased testosterone response rate, that is, a reduced percentage of patients not achieving castration testosterone levels of 50ng/dl compared with conventional formulations of LHRH agonists [16–18,20,23,30–32,37].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Eligard 1, 3, and 6 show an increased testosterone response rate, that is, a reduced percentage of patients not achieving castration testosterone levels of 20ng/dl compared with conventional formulations of LHRH agonists [16,17,19,20,30–32].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Eligard 1, 3, and 6 maintain low testosterone levels, that is, have a very low incidence of injection-related and breakthrough responses [30–32].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

6. Fig. 5
The majority of hot flushes reported during use of Eligard 1, 3, and 6 are of mild intensity [30–32].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

7. Fig. 6
The majority of delegates agreed with the statements “when initiating an LHRH agonist, my goal is to achieve ‘the lowest possible’ level of testosterone” () and “the testosterone suppression achieved is important when choosing between LHRH agonist formulations” ().
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions